---
title: "ITM and Telix merger creates $1.65B radiopharmaceutical contender after FDA setback"
id: "stat-news-0-stat-radiopharma-companies-merge-after-one-receives-surprise-fda-rejection"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-radiopharma-companies-merge-after-one-receives-surprise-fda-rejection"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/20/radiopharma-companies-itm-telix-merger/?utm_campaign=rss"
published_at: "2026-09-20T23:25:57.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# ITM and Telix merger creates $1.65B radiopharmaceutical contender after FDA setback
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-radiopharma-companies-merge-after-one-receives-surprise-fda-rejection
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/20/radiopharma-companies-itm-telix-merger/?utm_campaign=rss)
- **Published At:** 2026-09-20T23:25:57.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- ITM Isotope Technologies Munich SE and Telix Pharmaceuticals announced a merger in which Telix will acquire ITM, creating a larger player in the **radiopharmaceuticals** sector. - The deal is valued at at least $1.65 billion, with up to an additional $700 million payable to ITM shareholders if ITM’s lead drug achieves specified regulatory and sales milestones. - Under the agreement, Telix will acquire all shares of the privately held ITM. - The transaction follows a surprise FDA rejection of one company’s application; the source notes that the rejection prompted consolidation but does not provide detailed regulatory findings or which specific filing was rejected. - The merged company will join an industry landscape currently dominated by **Novartis**, which previously launched two radiopharmaceutical therapies in 2018 and 2022. - Radiopharmaceuticals target cancer by delivering radioactive isotopes directly to malignant cells; the article frames the deal as strengthening competition and resources in that therapeutic niche. - The source article is a STAT+ exclusive and is behind a subscriber paywall; additional deal details, management comments, and regulatory specifics were not reported in the available text. - Financial mechanics, integration plans, timelines for closing, and clinical-development status for ITM’s lead asset were not reported in the excerpt available from the source.
## Clinical Analysis & Structured Key Points
Radiopharma companies merge after one receives surprise FDA rejection Skip to Main Content STAT Plus Pharma Radiopharma companies merge after one receives surprise FDA rejection ITM Isotope Technologies to acquire Telix Pharmaceuticals in deal worth at least $1.65B Manage alerts for this article Save this story for later Share this article Camille MacMillin/STAT By Allison DeAngelis Sept. 20, 2026 Biotech Startups and Venture Capital Reporter Allison DeAngelis [email protected] Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “ The Readout Loud .” You can reach Allison on Signal at AllisonDeAngelis.01. ITM Isotope Technologies Munich SE and Telix Pharmaceuticals, two leading companies in the burgeoning radiopharmaceuticals field, are merging in a deal worth at least $1.65 billion. Under the deal, Telix will acquire all shares of the privately held company ITM. Telix could also pay another $700 million to shareholders, if ITM’s lead drug meets regulatory and sales goals. Advertisement The merger creates another well-resourced company in the radiopharmaceutical field, which is currently dominated by Novartis. These medicines work by delivering radioactive isotopes directly to cancer cells. Novartis supercharged the field with the launch of its two such treatments in 2018 and 2022. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in Individual plans Group plans Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology , Cancer , Pharmaceuticals , STAT+ Submit a correction request Reprints Allison DeAngelis Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “ The Readout Loud .” You can reach Allison on Signal at AllisonDeAngelis.01. Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our Privacy Policy and Terms of Service . You may opt out of receiving STAT communications at any time. Recommended The Readout The Readout September 18, 2026 STAT Plus: Roche expands its Boston footprint with new research center Biotech Biotech September 17, 2026 STAT Plus: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease Advertisement The Readout The Readout September 17, 2026 STAT Plus: New startup to test psychedelic-like drug against Parkinson’s symptom Adam's Biotech Scorecard Adam's Biotech Scorecard September 17, 2026 STAT Plus: A Sellas immunotherapy study, long delayed, will end in failure Adam's Biotech Scorecard Adam's Biotech Scorecard September 17, 2026 STAT Plus: A biotech hedge fund births a new immunology company Subscriber Picks
## Related Clinical Research

- [Cross-species spatial profiling implicates progranulin in immune-suppressive niches of brain metas](https://medichelpline.com/clinical-feed/biorxiv-0-cross-species-spatial-profiling-links-progranulin-to-an-immune-suppressive.md)
- [Rare genetic variant linked to 25-fold higher lung cancer risk in never-smokers](https://medichelpline.com/clinical-feed/stat-news-0-stat-why-do-never-smokers-get-lung-cancer-in-some-cases-rare-genetic-variant.md)
- [Spatial transcriptomics reveals invasion-associated programs across malignant progression in IDH‑m](https://medichelpline.com/clinical-feed/biorxiv-0-spatially-resolved-gene-expression-and-tumour-microenvironment-interactions.md)
- [Daraxonrasib shows activity in RAS‑mutant NSCLC after FDA approval in pancreatic cancer](https://medichelpline.com/clinical-feed/medical-news-today-0-pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer.md)
- [Replacing animal fats with plant fats linked to lower mortality after nonmetastatic prostate cancer](https://medichelpline.com/clinical-feed/medical-news-today-0-swapping-animal-fats-with-plant-fats-may-lower-risk-of-death-after-prostate.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.